Details

<p>List of Contributors, vii</p> <p>1 What is non-alcoholic fatty liver disease (NAFLD), and why is it important? 1<br /> <i>Geoffrey C. Farrell, Arthur J. McCullough, and Christopher P. Day</i></p> <p>2 NAFLD in the community, 17<br /> <i>Leon A. Adams</i></p> <p>3 Pathology of NAFLD, 27<br /> <i>Elizabeth M. Brunt and David E. Kleiner</i></p> <p>4 The natural history of NAFLD, 37<br /> <i>Paul Angulo</i></p> <p>5 Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH), 46<br /> <i>Isabelle A. Leclercq</i></p> <p>6 Diabetes and NAFLD: why is the connection important? 62<br /> <i>Elisabetta Bugianesi</i></p> <p>7 NAFLD and cardiovascular risk factors: implications for vascular disease, 71<br /> <i>Giovanni Targher</i></p> <p>8 A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer, 84<br /> <i>Shivakumar Chitturi and Geoffrey C. Farrell</i></p> <p>9 Imaging of NAFLD, 93<br /> <i>Takeshi Yokoo, An Tang, and Claude B. Sirlin</i></p> <p>10 Non-invasive methods to determine the severity of NAFLD and NASH, 112<br /> <i>Vincent Wai-Sun Wong and Henry Lik-Yuen Chan</i></p> <p>11 Fatigue, quality of life, and psychosocial issues for people with NAFLD, 122<br /> <i>Julia L. Newton and James Frith</i></p> <p>12 Physical activity and cardiovascular fi tness in patients with NAFLD: clinical importance and therapeutic implications, 132<br /> <i>Ingrid J. Hickman, Graeme A. Macdonald, and Nuala M. Byrne</i></p> <p>13 NAFLD, obesity, and bariatric surgery, 149<br /> <i>Philippe Mathurin</i></p> <p>14 Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management, 157<br /> <i>Quentin M. Anstee, Ann K. Daly, and Christopher P. Day</i></p> <p>15 NAFLD in children, 171<br /> <i>Ariel E. Feldstein</i></p> <p>16 The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure, 182<br /> <i>Jonathon W. Schwake, Dawn M. Torres, and Stephen A. Harrison</i></p> <p>17 Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers, 192<br /> <i>Janine Graham and Helen L. Reeves</i></p> <p>18 NAFLD in Chinese and South Asian people, 206<br /> <i>Jia-Horng Kao, Deepak Amarapurkar, and Jian-Gao Fan</i></p> <p>19 Non-alcoholic fatty liver disease in Japan, 217<br /> <i>Takeshi Okanoue, Kohichiroh Yasui, and Yoshito Itoh</i></p> <p>20 Non-alcoholic fatty liver disease in South America and Hispanic people, 228<br /> <i>Helma Pinchemel Cotrim and Carla Daltro</i></p> <p>21 Alcohol in non-alcoholic fatty liver disease: an oxymoron or a new standard of care?, 234<br /> <i>Achuthan Sourianarayanane, Srinivasan Dasarathy, and Arthur J. McCullough</i></p> <p>22 Dietary factors in the pathogenesis and care of patients with fatty liver disease, 248<br /> <i>Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli, and Silvia Di Domizio</i></p> <p>23 Metabolic factors and steatosis in patients with hepatitis B and C, 260<br /> <i>Francesco Negro</i></p> <p>24 Drug therapy for NASH: insulin-sensitizing agents (metformin and thiazolidinediones), 271<br /> <i>Mohammad S. Siddiqui and Arun J. Sanyal</i></p> <p>25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines, 284<br /> <i>Anne Catherine Bürgi and Jean-François Dufour</i></p> <p>26 Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents, 293<br /> <i>Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, and Maurizio Cassader</i></p> <p>Index, 308</p> <p>Color plate section facing p86</p>

<p>“This book is useful for anyone who cares for patients with NAFLD -- specialist or generalist. It provides both a general overview as well as a detailed look at disease mechanisms, clinical assessment, diagnosis, and treatment. It comes out in a timely fashion as diseases such as diabetes, obesity, metabolic syndrome, NAFLD, and NASH are on the rise.”  (<i>Doody’s</i>, 24 January 2014)</p>

<p><b>Geoff Farrell, Professor of Hepatic Medicine, Director of Gastroenterology, The Canberra Hospital, Australia</b><br />Geoffrey Farrell graduated MB BS from the University of Tasmania in 1970, and trained in gastroenterology and hepatology at the Royal Prince Alfred and Royal Brisbane Hospitals, the latter with Lawrie Powell with whom he completed an MD on hepatic drug metabolism. He was awarded an NHMRC CJ Martin Fellowship to conduct post-doctoral research in UCSF, and in 1980 returned to Sydney to establish a Liver Research Group at Westmead Hospital. He was promoted to a personal chair in 1993, then accepted the Storr Chair in Hepatic Medicine. He remained Director of the Storr Liver Unit until Jan 2006, when he accepted the position as Professor of Hepatic Medicine with ANU Medical School and Director of Gastroenterology and Hepatology at The Canberra Hospital. He has held many leadership roles in medical research, gastroenterology, editorial boards, and academic medicine, including Editor-in-Chief of <i>Journal of Gastroenterology and Hepatology</i> since November 2006.<br />Geoff Farrell's research interests are in non-alcoholic steatohepatitis, viral hepatitis, drug-induced liver injury, and liver regeneration. He has published 3 books, including the first on non-alcoholic fatty liver disease, and written more than 180 scientific papers and 100 reviews/chapters and editorials in the fields of hepatology and biochemical pharmacology. His work is very highly cited, with an H-index of 50, more than 20 articles cited >100 times, average citation 32 per paper, and 15 articles being the subject of editorials in major medical journals. He is CIA on an NHMRC Program Grant to study the molecular and cellular basis of liver disease, and has recently held a Centre for Clinical Research Excellence Program grant to improve outcomes for patients with liver disease.</p> <p><b>Arthur McCullough, Department Chair of Gastroenterology and Hepatology, Cleveland Clinic, USA</b><br />Arthur McCullough, MD, is Department Chair of Gastroenterology and Hepatology and a Staff Physician in the Department of Pathobiology and Transplantation Center at Cleveland Clinic. He was appointed in 2006. He attended medical school at SUNY Health Science Center at University Hospital of Syracuse, N.Y. He completed his internship and residency at Cleveland Clinic and a fellowship at Mayo Clinic in Rochester, Minn.<br />He is one of the most senior hepatologists in the United States and is the current President of the American Association for the Study of Liver Diseases. Other significant achievements are: Best Doctor's in America: "Midwest Region" annually from 1996-2008; Chair of the NIH-funded Clinical Research Network on Fatty Liver Disease (federal funding); NIH Grant on Omega 3 Fatty Acids in Diabetes (federal funding); New Novel Agents for Hepatitis C Patients who failed to respond to previous therapy (non-federal funding)</p> <p><b>Christopher Day, Pro-Vice-Chancellor for the Faculty of Medical Sciences, Professor of Liver Medicine and Consultant Hepatologist, School of Clinical Medical Sciences, Newcastle University, UK</b><br />Chris Day qualified from Cambridge University in 1983 and subsequently trained in General Medicine and Hepatology at Newcastle, becoming Consultant Hepatologist in the Liver Unit at Newcastle’s Freeman Hospital in 1994 and Professor of Liver Medicine at University of Newcastle University in 2000. He was formerly Head of the School of Clinical Medical Sciences at the University and since April 2008 has been Pro-Vice-Chancellor of the Faculty of Medical Sciences. Professor Day's research interests focus largely on fatty liver disease related both to obesity and to alcohol, with additional interests in drug-induced liver injury and liver fibrosis. His work has been funded by the MRC and the Wellcome Trust and he is a former MRC Clinical Training Fellow and Clinician Scientist Fellow. In 1999 he was the Goulstonian Lecturer of the Royal College of Physicians and in 2000 was awarded the research gold medal of the British Society of Gastroenterology. He is a Fellow and Councillor of the Academy of Medical Sciences, an Executive Member of the Medical Schools Council and an NIHR Senior Investigator. He is also Chief Editor of the <i>Journal of Hepatology</i>, and is on both the Populations and Systems Medicine Board and the Translational Stem Cell Research Committee of the Medical Research Council.</p>

<p><i>Do you have patients referred to you suffering from NAFLD?<br /> </i><i>Are you looking for an expert guide to the latest in clinical management?</i></p> <p>If so, this is the book for you, providing an expert and comprehensive analysis of NAFLD: what it is, why it happens, who is likely to suffer from it, and how to decide on the best management options for your patients.</p> <p>This book focuses clearly on providing first-rate clinical guidance as to the assessment, diagnosis and treatment of patients in the clinical setting, based wherever possible on the latest evidence and scientific understanding of disease mechanisms.  With each chapter fully revised and updated with the very latest in AASLD,  EASL and Asia-Pacific guidelines, this second edition provides:</p> <ul> <li>Four brand new chapters, including “NAFLD and cardiovascular risk factors” and “Non-invasive methods to determine severity of NAFLD/ NASH”</li> <li>A clear overview on the causative mechanisms of NAFLD</li> <li>Self-assessment via key points and multiple-choice questions throughout</li> <li>The very latest in clinical drug trials</li> <li>Analysis of NAFLD in relation to obesity, diabetes, high cholesterol and liver cancer</li> <li>A consideration of NAFLD importance in Asia (particularly including Japan and China) and South America, as well as Europe and North America</li> </ul> NAFLD is a serious condition that is increasing in prevalence globally from year to year<i>.  Non-Alcoholic Fatty Liver Disease:</i> <i>A Practical Guide,</i> is essential reading for all hepatologists and health professionals managing patients who have this condition.

GB